Vycor Announces First Release of NovaVision(R)'s Saccadic NeuroEyeCoach(TM) Therapy
November 07 2013 - 10:09AM
Marketwired
Vycor Announces First Release of NovaVision(R)'s Saccadic
NeuroEyeCoach(TM) Therapy
Full Commercialization and Product Availability on Track by Year
End
BOCA RATON, FL--(Marketwired - Nov 7, 2013) - Vycor Medical,
Inc. ("Vycor") (OTCQB: VYCO), a medical device company with a suite
of FDA cleared products, announced the first release of its new
"direct to the patient" saccadic eye training program to be
marketed as NeuroEyeCoach™.
The Company further confirmed that the Internet-based program
was on track to be commercially available by year-end
2013. NeuroEyeCoach™ will also be available in an
institutional version designed for use at rehabilitation and
medical centers. The development work on the institutional version
has also been completed.
Commenting on the Company's announcement, David Cantor,
President of Vycor, stated, "Having completed the development of
NeuroEyeCoach™, we are on track to have full commercialization and
availability of both a retail and institutional rehabilitation
product by the end of 2013. We believe that NeuroEyeCoach™ will
address a very substantial and under-served market. The retail
version of NeuroEyeCoach™ will be available to patients via the
Internet allowing for therapy to take place in the comfort of their
home. We believe this will be the first such commercially available
product offered via the Internet."
Vycor's wholly-owned NovaVision® subsidiary is the worldwide
leader in the field of vision rehabilitation in the U.S., Europe,
and other global markets. In addition to NeuroEyeCoach™,
NovaVision® develops and markets a non-invasive, computer-based
light stimulation therapy called Vision Restoration Therapy
(VRT™). NovaVision's VRT™ is the only medical device aimed at
the restoration of vision for neurologically induced vision loss
which has FDA 510(k) clearance to be marketed in the U.S.
The NeuroEyeCoach™ therapy is highly complementary to VRT™. The
two therapies address different visual disabilities each of which
results from neurologically-induced vision loss -- a loss of visual
field as well as difficulty with eye movement, affecting the
ability to integrate visual information. VRT provides partial
restoration of the patient's lost visual field. NeuroEyeCoach™ has
been specifically developed to increase the efficiency of eye
movement and re-train the patients' ability to integrate visual
information between the left and right hand side.
The eventual inclusion of NeuroEyeCoach™ into the patients'
overall therapy regime along with VRT therefore addresses two key
visual disabilities and will enable a significant positive impact
in a patient's interaction with their environment and hence their
ability to successfully perform their daily living activities.
The Company is in parallel actively working on re-engineering
its VRT to also enable it for direct-to-the-patient Internet
delivery and to streamline a number of business processes related
to the delivery and servicing of patients, although the therapy
itself will remain unchanged. Once completed, NovaVision plans to
offer both NeuroEyeCoach™ and VRT alongside each other in one
therapy suite creating the most robust, affordably available
Internet-based visual therapy solution targeted at neurologically
induced vision loss.
NeuroEyeCoach™ is a result of collaboration between Vycor
management and its world class NovaVision Scientific Advisory
Board.
About Vycor Medical, Inc.
Vycor Medical, Inc. ("Vycor") is dedicated to providing the
medical community with innovative and superior surgical and
therapeutic solutions and has a growing portfolio of FDA-cleared
medical solutions that are changing and improving lives every day.
The Company operates two wholly-owned business units: Vycor Medical
and NovaVision®, both of which adopt a minimally or non-invasive
approach. Both technologies have exceptional sales growth
potential, address large potential markets, have the requisite
regulatory approvals and are commercialized and generating
revenue.
Vycor Medical's flagship, ViewSite™ Surgical Access Systems
(VBAS) is a suite of clear cylindrical minimally invasive
disposable devices that hold the potential for speedier, safer and
more economical brain surgeries and a quicker patient
discharge. VBAS is designed to optimize neurosurgical site
access, reduce patient risk, accelerate recovery and add tangible
value to the professional medical community. Vycor Medical is ISO
13485:2003 compliant, has FDA 510(k) clearance for VBAS for brain
and spine surgeries and regulatory approvals for brain surgeries in
Australia, Canada, China, Europe, Japan, Korea and Russia. For an
overview of Vycor Medical's VBAS see
http://player.vimeo.com/video/39766887
NovaVision® develops and provides science-driven
neurostimulation therapy and other medical technologies that help
improve and partially restore sight in patients with neurological
vision impairments. The company's proprietary Visual
Restoration Therapy® (VRT) platform is clinically supported to
improve lost vision resulting from stroke, traumatic brain injury
("TBI"), or other acquired brain injuries. VRT is the only FDA
510(k) cleared medical device in the U.S. aimed at the restoration
of vision for neurologically induced vision loss and can be
prescribed by any ophthalmologist, optometrist, neurologist or
physiatrist. VRT also has CE Marking for the EU. NovaVision is
also developing NeuroEyeCoach™, a new Internet-based "direct to the
patient" saccadic eye training program which is expected to be
commercially available by year-end 2013. The Company also provides
Neuro-Eye Therapy (NeET) in the EU, aimed at increasing visual
sensitivity deep within the field defect. For an overview of
NovaVision see http://player.vimeo.com/video/39765566
For the latest information on the company, including media and
other coverage, and to learn more, please go online at
www.vycormedical.com or www.novavision.com.
Safe Harbor Statement
Information in this document constitute forward-looking
statements or statements which may be deemed or construed to be
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. The words "forecast",
"anticipate", "estimate", "project", "intend", "expect", "should",
"believe", and similar expressions are intended to identify
forward-looking statements. These forward-looking statements
involve, and are subject to known and unknown risks, uncertainties
and other factors which could cause Vycor Medical's actual results,
performance (financial or operating) or achievements to differ from
the future results, performance (financial or operating) or
achievements expressed or implied by such forward-looking
statements. The risks, uncertainties and other factors are more
fully discussed in Vycor Medical's filings with the U.S. Securities
and Exchange Commission. All forward-looking statements
attributable to Vycor Medical herein are expressly qualified in
their entirety by the above-mentioned cautionary statement. Vycor
Medical disclaims any obligation to update forward-looking
statements contained in this estimate, except as may be required by
law.
Vycor Medical, Inc. Investor Contacts: The Del Mar Consulting
Group, Inc. Robert B. Prag President 858-794-9500 Email Contact or
Alex Partners, LLC Scott Wilfong President 425- 242-0891 Email
Contact
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jun 2024 to Jul 2024
Vycor Medical (QB) (USOTC:VYCO)
Historical Stock Chart
From Jul 2023 to Jul 2024